Volume 32, Number 3—March 2026
Dispatch
Emerging Endemic Area for Blastomycosis, New York, USA, 2000–2024
Laura E. Ramirez
, Christian Kostowniak, Jessica Kumar, Sudha Chaturvedi, Ananthakrishnan Ramani, and Amit Chopra
, Christian Kostowniak, Jessica Kumar, Sudha Chaturvedi, Ananthakrishnan Ramani, and Amit Chopra
Table 2
Diagnostic evaluation and treatment patterns for patients with isolated and disseminated laboratory-confirmed blastomycosis reported in Albany, New York, USA, 2000–2024*
| Characteristics | Isolated pulmonary | Disseminated | Total |
|---|---|---|---|
| Mean age + SD, y |
45 + 17 |
40 + 19 |
43 + 18 |
| Sex | n = 24 | n = 28 | n = 52 |
| F | 7 (29) | 4 (14) | 11 (21) |
| M |
17 (71) |
24 (86) |
41 (79) |
| Method of specimen collection | n = 23 | n = 28 | n = 51 |
| Biopsy | 17 (71) | 25 (89) | 42 (82) |
| Bronchioalveolar lavage | 14 (58) | 3 (11) | 17 (32) |
| Sputum | 2 (8) | 1 (4) | 3 (6) |
| Lumbar puncture |
0 |
3 (11) |
3 (6) |
| Methods of establishing diagnosis | n = 22 | n = 28 | n = 50 |
| Real-time PCR | 17 (77) | 22 (79) | 39 (78) |
| Culture | 12 (55) | 17 (61) | 29 (58) |
| Histopathology and cytopathology |
6 (27) |
7 (25) |
13 (26) |
| Computed tomography chest characteristics | n = 24 | n = 12 | n = 36 |
| Mass | 8 (33) | 5 (42) | 13 (36) |
| Lobar consolidation | 9 (38) | 3 (25) | 12 (33) |
| Nodular | 7 (29) | 4 (33) | 11 (31) |
| Pleural effusion | 3 (13) | 3 (25) | 6 (17) |
| Mediastinal lymphadenopathy | 2 (8) | 2 (17) | 4 (11) |
| Cavity | 3 (13) | 0 | 3 (8) |
| Miliary |
1 (4) |
1 (8) |
2 (6) |
| Treatment | n = 19 | n = 21 | n = 40 |
| Itraconazole only | 13 (68) | 11 (53) | 24 (60) |
| Amphotericin B followed by itraconazole | 4 (21) | 6 (29) | 11 (28) |
| Amphotericin B only | 2 (11) | 2 (10) | 4 (10) |
| Fluconazole | 0 | 2 (10) | 2 (5) |
| Voriconazole |
1 (5) |
0 |
1 (3) |
| Length of treatment, n = 31 | n = 15 | n = 16 | n = 31 |
| 6 mo | 7 (47) | 1 (6) | 8 (26) |
| 9 mo | 0 | 1 (6) | 1 (3) |
| 12 mo |
8 (53) |
14 (88) |
22 (71) |
| Death |
1 (2) |
2 (4) |
3 (6) |
| Total | 24 (46) | 28 (54) | 52 |
*Values are no. (%) except as indicated. Categories are not mutually exclusive, so totals may sum to >100%. Data were not available for all variables for every patient; therefore, denominators vary by category. Percentages are calculated by using the number of patients with available data for each variable.
Page created: February 11, 2026
Page updated: March 20, 2026
Page reviewed: March 20, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.